Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the...
John P. Thomas, A. Saifuddin, Sadek Malas et al.· JCC Plus· 0 citations
The evolving role of FMT within the therapeutic framework of chronic inflammation, focusing specifically on IBD, is examined and the variable clinical outcomes in IBD are compared with the highly successful model of recurrent CDI, highlighting mechanistic and clinical determinants of response in a different disease con...
Anum Javed, Despoina Chrysostomou, J. Marchesi et al.· Inflammatory Bowel Diseases· 0 citations
Ulcerative colitis (UC) is characterised by chronic colonic inflammation with marked heterogeneity in disease severity and therapeutic outcomes. Here, we define a spatially organised, polyfunctional cytotoxic CD4⁺ T-cell state associated with mucosal inflammation and adverse therapeutic outcomes in UC. Integrating ex v...
John P Thomas, S. H. Kottoor, Jonathan W. Lo et al.· bioRxiv· 0 citations
This review synthesizes current mechanistic and translational evidence to conceptualize the gut microbiome as an organ‐like functional system, delineate its structural and functional organization, and propose a framework for mapping, modeling, and therapeutically targeting microbiome‐derived circuits to support precisi...
Yang Bi, Wei-Bin Song, Maria Glymenaki et al.· iMeta· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.